Palvella Therapeutics. products

QTORIN^TM rapamycin 3.9% is a novel topical therapy being studied for Pachyonychia Congenita (PC). We are currently enrolling our phase 3 study in PC.

QTORIN™ rapamycin 3.9%is a novel targeted topical therapy being studied for Gorlin syndrome. Palvella is enrolling a phase 2b clinical study (CODY) for people with Gorlin syndrome.

QTORIN™ rapamycin 3.9% is a novel targeted topical therapy being studied for Microcystic Lymphatic Malformations (Micro LM). Palvella is enrolling a phase 2 clinical study for people with Micro LM.